cyrilzakka/clinical-trials huggingface dataset:
Variability of Healthy People and People After Stroke Results in the Nine Hole Peg Test

Main aim of the study is to find out how many attempts of each subtest in the Nine Hole Peg Test should be done in clinical practice during testing people after stroke who are 20-64 years old.


Eligibility Criteria:
Inclusion Criteria:

* age: 20-64 years (inclusive)
* hospitalized patient in Rehabilitation Centre Kladruby
* women and men with Czech as their mother tongue
* signed Informed consent
* ability to maintain a stable sitting position for the duration necessary for testing
* comprehension of verbal instructions and recordings for the Nine Hole Peg Test

Exclusion Criteria:

* inability to successfully complete a pilot attempt of the Nine Hole Peg Test using the right and left hand
* severe spastic paresis of the upper limb, which would make the test impossible
* plegia of the upper limb
* failure to complete the test to visual or hearing impairment
* inability to understand verbal instructions
* inability to maintain attention during testing
* severe attention deficit disorder
* neglect syndrome
* fatigue
* external factors that prevent the complete completion of the test
CLearing Alzheimer's Disease Molecular Pathology Without Medications

According to the most popular pathophysiological models of Alzheimer's disease, the amyloid hypothesis, amyloid deposition is the causative event triggering a chain of other downstream events which finally lead to Alzheimer's disease and dementia. In mouse models of Alzheimer's disease, 40 Hz multi-sensory (auditory and visual) stimulation was able to reduce the number and size of amyloid plaques throughout cortex and improve cognitive performance.

The primary objective of this study is to assess whether an intervention consisting of 40 Hz multi-sensory (auditory and visual) stimulation is able to reduce the amyloid load in non-demented amyloid-positive individuals.

As secondary objectives, the investigators will assess whether such intervention is able to:

* improve the brain electrical activity,
* improve or slow down the worsening of Alzheimer's blood-based biomarkers,
* improve or slow down the worsening of cognition.


Eligibility Criteria:
Inclusion Criteria:

* Informed Consent as documented by signature (Appendix Informed Consent Form),
* age 40-80,
* ≥5 years of education,
* previous evidence of brain amyloidosis (assessed by PET, CSF, or blood-based biomarkers).

Exclusion Criteria:

* history of epilepsy;
* clinically relevant visual or auditory diseases/deficits;
* clinical diagnosis of dementia;
* contraindication to amyloid-PET;
* inability to undergo the procedures of the study, e.g. severe behavioral disturbances;
* severe diseases:

  1. Malignant neoplasm within 5 years,
  2. Life threatening diseases,
  3. Severe systemic diseases (e.g. kidney insufficiency, cardiac insufficiency, decompensated diabetes, decompensated metabolic diseases, decompensated hypothyroidism, uncontrolled autoimmune diseases);
* the participation to a clinical trial involving potential Alzheimer's disease modifying therapies;
* documented pregnancy or intention to become pregnant during the course of the study or breast feeding.
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.


Eligibility Criteria:
Inclusion Criteria

* Generally healthy men and women of nonchildbearing potential (WONCBP), aged 18 to 50 years.
* Body Mass Index (BMI) range of 18 to 30 kg/m2.
* Blood serum creatinine levels less than or equal to the upper limit of normal.

Exclusion Criteria

* Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
* Any history of clinically important cardiac arrhythmias and familial history of long QT syndrome or unexpected cardiac death.
* History of drug and alcohol abuse, positive HIV, HCV, and/or HBs Ag test, and any clinically important deviation from normal limits in physical examination, vital signs, 12-lead ECGs, or clinical laboratory test results.
Chlorhexidine Gluconate Versus Povidone Iodine at Cesarean Delivery: a Randomized Controlled Trial

Currently there are no published studies comparing the efficacy of Chloraprep and povidone-iodine in decreasing postoperative- wound infection in cesarean sections. However, there have been studies involving other types of surgery that have compared the efficacy of different types of preoperative cleansing agents in preventing postoperative wound infection. These studies have shown that controversy exists over which antiseptic skin preparation is the most effective for preventing postoperative surgical wound infections. The standard of care at Los Angeles County Hospital for preoperative skin antiseptic in cesarean sections is povidone- iodine 10% (betadine), however many other hospitals have made the transition to using Chloraprep. In an attempt to improve on the current standard of care, we propose a quality improvement prospective randomized study to compare the difference in postoperative wound complications with the use of povidone- iodine and Chloraprep as a preoperative antiseptic in cesarean sections. We hypothesize that Chloraprep will be better than Betadine at reducing the incidence of positive bacterial cultures following cesarean sections.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant women greater than 36 weeks gestation presenting for scheduled repeat cesarean sections and scheduled primary cesarean sections
* Ages 18-45
* Written informed consent obtained

Exclusion Criteria:

* Patients who are taking antimicrobial therapy for any reason
* Patient with a known allergy to one or both of the prepping agents
* Patients currently taking immunosuppressant drugs
* Active acute or chronic infection
* Current history of cancer
* Open wounds, skin ulcers, sores, and severe acne
* History of methicillin-resistant staphylococcus aureus colonization or oxacillin-resistant staphylococcus aureus colonization
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells, including lymphokine-activated killer cells, to kill tumor cells. Giving cellular adoptive immunotherapy during or after surgery may kill more tumor cells.

PURPOSE: This phase II trial is studying how well cellular adoptive immunotherapy works in treating patients with glioblastoma multiforme.

OBJECTIVES:

* Determine the feasibility, side effects, and toxicity associated with intracranial cellular adoptive immunotherapy comprising aldesleukin-stimulated lymphokine-activated killer cells in patients with glioblastoma multiforme.
* Determine progression-free and overall survival of these patients.
* Compare survival of these patients to that of contemporary and historical controls.

OUTLINE: Patients undergo therapeutic craniotomy.

Patients undergo leukapheresis to obtain lymphokine-activated killer (LAK) cells 3-7 days before therapeutic craniotomy OR 4-6 weeks after therapeutic craniotomy. Patients receive cellular adoptive immunotherapy comprising aldesleukin-stimulated LAK cells intracranially at the time of therapeutic craniotomy OR via an Ommaya reservoir (placed during craniotomy) no sooner than 4-6 weeks after therapeutic craniotomy.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of primary malignant glioblastoma multiforme (i.e., grade IV anaplastic astrocytoma)
* Primary treatment (surgery, radiation, and/or chemotherapy) has been completed
* Candidate for surgery and willing to undergo craniotomy
* No progressive or recurrent disease
* No residual disease that requires reoperation, additional gamma therapy, or other modality

PATIENT CHARACTERISTICS:

* ECOG performance status (PS) 0-2 OR Karnofsky PS 70-100% (i.e., if symptomatic, bedridden \< half of a waking day)
* Life expectancy ≥ 2 months
* Not pregnant
* Negative pregnancy test
* U.S. residents only
* No hematopoietic, hepatic, renal, cardiovascular, or pulmonary laboratory values or other medical circumstances that would preclude surgery or aldesleukin therapy
* No serious concurrent medical or psychiatric illness that would preclude informed consent or study treatment

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 4 weeks since prior anticancer therapy and recovered
* Prior stereotactic or gamma knife radiosurgery allowed
Message Framing and Policy Support for Front-of-package Labeling

This study aims to assess whether different message framing about front-of-package labeling policies elicits more policy support than the control (no framing) among Latino and limited English proficiency populations. The study also seeks to identify which message framing elicits the most policy support.

Participants will complete a between-subjects online randomized experiment. Participants will be randomized to 1 of 4 arms: 1) No framing (control), 2) Information framing, 3) Healthier choices framing, and 4) Industry framing. In each arm, participants will view 1 message developed for their randomly assigned arm and indicate their policy support.

Eligibility Criteria:
Inclusion Criteria:

* Identifying as Latino or Hispanic
* Ages 18-55 years old
* Residing in the United States

Exclusion Criteria:

* Not identifying as Latino or Hispanic
* Less than 18 or greater than 55 years old
* Not residing in the United States
The Second Try During Landmark Approach of the Internal Jugular Vein: an Ultrasonographic Prelocation Study

Two approaches are possible when the first finder needle attempt of the internal jugular vein cannulation fails; the needle can be turned slightly laterally or the puncture point can be moved slightly medially. This study is an ultrasonographic stimulation study to evaluate the success rate of turning the needle laterally and moving the puncture point medially, and to determine the proper angle or distance for the second try of internal jugular vein cannulation.

Immediately after induction of general anesthesia, the patient's head is turned slightly, and the table is tilted at 10 degrees, and the puncture point estimated by the anatomical landmarks are marked on the patient's skin. The investigators obtain a sonographic view at the estimated puncture point. It is recorded "success" when the internal jugular vein is visualized on the ultrasonography, and the estimated needle path passes the internal jugular vein. It is recorded "failure" if the internal jugular vein is not visualized on the ultrasonography, and the estimated needle path does not pass the internal jugular vein. After "failure" of the first attempt, the probe is either turned laterally or moved medially until the internal jugular vein is visualized on the ultrasonography, and the estimated needle path passes the internal jugular vein. The angle and distance is recorded. The location of the carotid artery is always marked on the ultrasonography for evaluation of complications.

Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for general anesthesia

Exclusion Criteria:

* Refusal of consent
* Patients with C-spine injuries
* Patients with atlanto-axial instability
* Patients at risk of increased intracranial pressure
Detection of Microdeletions in the Azoospermia Factor (AZF) Regions in Infertile Male Patients

In this prospective study, we used Multiplex ligation-dependent probe amplification and next-generation sequencing technology to detect AZF microdeletion types accurately in selected genetic locus, and made correlation analysis with clinical treatment results.

Infertility has plagued more than 10% of the world's couples of childbearing age, of which male factors account for half. There are many causes of male infertility, including infection, genital malformations, immune dysfunction, varicocele, erectile dysfunction, drug side effect and chromosomal abnormality. Microdeletion of Azoospermia factor (AZF) in the long arm of the Y chromosome is one of the main genetic factors leading to dyszoospermia. The incidence of AZF microdeletions is 2%\~19.4% among male infertile patients in Asia, which is related to the inclusion criteria, STS site selection, population and genetic background.

At present, there are large numbers of studies on AZF microdeletions in male infertility, and provide rich information on male infertility. However, as the main means of detection is multiplex PCR-capillary electrophoresis method, which usually detects sequence-tagged sites(STS) such as AZFa-sY84，sY86，AZFb-sY127，sY134，AZFc- sY1191, sY1291, sY1189,sY254 and sY255, information on other loci is still lacking.

In addition, the shortcomings of this method include false positive and false negative results caused by fuzzy electrophoresis strip or pollution and the presence of high repetition and a large number of palindrome in complex AZF region. Because some microdeletions can't be detected it is difficult to make an accurate judgement on the fertility of the patients.

This study will use Multiplex ligation-dependent probe amplification and NGS method to improve the detection rate of AZF microdeletion, and analyze the microdeletion data and the patient's fertility results, so as to improve genetic counseling. A total of 5000 male infertility patients will be enrolled. At least 1000 parents and 1000 normal fertile men will be asked to donate their peripheral blood for DNA.

In addition, in patients with azoospermia or severe oligozoospermia, the overall deletion rate of AZF is about 8.77% (1.75%-24.70%), so there are other unknown genetic factors leading to azoospermia or severe oligozoospermia. This study will also try to make a preliminary study of these factors.

Eligibility Criteria:
Inclusion Criteria:

-Male patients diagnosed with azoospermia and severe oligozoospermia.

Exclusion Criteria:

1. Klinefelter Syndrome ;
2. Structural chromosome aberrations；
3. Obstructive anspermia;
4. Male infertility caused by endocrine factors;
5. Do not meet requirements for acquisition, processing and preservation of samples；
6. After sampling, it doesn't conform to the standard of quality control, or other experimental conditions that don't meet the test requirement；
7. Unable to obtain patient history;
Metabolic Effects of Stevia in Type 2 Diabetic Patients

The main aim of the study is to assess the short term and 1-month metabolic effects of Stevia rebaudiana bertoni in patients with type 2 diabetes.

This is a non-randomized clinical trial in a type 2 diabetic population aiming to investigate the effect of Stevia rebaudiana bertoni on the glycaemic and insulin secretory response to a mixed meal tolerance test, insulin sensitivity and lipid profile. The study has two arms including an intervention arm (test group) and a non-intervention arm (controls) matched for age, sex and body mass index in 2:1 ratio.

The intervention is made of two phases including

1. A mixed meal tolerance test with and without 240 mg of Stevia in a randomized order to evaluate the acute effects;
2. An oral intake of 240 mg of Stevia within 30 days as food supplement in order to assess medium-term effects

Eligibility Criteria:
Inclusion Criteria:

* Known type 2 diabetes
* Unchanged hypoglycaemic treatment for at least 3 months prior to inclusion
* No acute complication of diabetes
* HbA1C≤ 8%

Exclusion Criteria:

* Infection up to 10 days prior to inclusion
* Serum ALAT \>3N,
* MDRD estimated creatinine clearance \<60ml/min
* Tobacco smoking
Response Of Arteriovenous Fistula Puncture-related Pain To Cryotherapy Application In Haemodialysis Patients

Kidney disease occurs when kidney reduces its normal function, less than 30% of normal activity is related to a long-term condition. Therefore, people need to participate in a haemodialysis (HD) programme. In HD, blood is filtered by an external machine, done about three times a week and the access is gained through intermittent vascular cannulation.

The patients experience considerable pain due to the frequent insertion of AVF catheters.

Hemodialysis patients experience anxiety before needle insertion due to repeated punctures, and over 90% of patients experience acute pain during the process.

Puncture-related pain during arteriovenous fistula (AVF) cannulation in particular is a crucial influential factor in quality of life.

Cryotherapy is one of the interventions used in several studies to alleviate the arteriovenous fistula puncture-related pain. It can be conduct by using ice packs and the results of the previous studies have also shown its positive effects on the relief of the fistula puncture-related pain in these patients.

Ninety male and female patients with end stage renal disease randomly assigned into three equal groups (n=30) their ages ranged between 30-50:

1. Group A (30 patients) receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.
2. Group B (30 patients) receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.
3. Group C (30 patients) it is a control group this group not received ice pack.

Eligibility Criteria:
Inclusion Criteria:

* The study includes patients with ages from 30 to 50 years.
* Patients able to report pain adequately.
* Patients with end-stage kidney failure undergoing regular hemodialysis who have been treated for more than 3 months, at least twice per week, with arteriovenous fistula in use for more than 1 month are included in the study.

Exclusion Criteria:

Patients with conditions such as

* advanced age,
* advanced diabetes,
* cardiovascular insufficiency,
* cold allergy,
* Reynaud's phenomenon,
* nerve and tissue damage,
* fractures,
* heart failure,
* uncooperative patients,
* cognitive impairment preventing a proper assessment of pain.
A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

The purpose of this study is to test the safety and effectiveness of MK-6213 as compared to MK-6213/Atorvastatin in participants 18 to 75 years) with high cholesterol.


Eligibility Criteria:
Inclusion Criteria:

* 18 to 75 years of age at the time of the study with high cholesterol
* Can have diabetes mellitus but is not currently on lipid lowering therapy
* Have a stable weight for \>6 weeks

Exclusion Criteria:

* Has significant cardiovascular (heart), renal (kidney), neurologic (nervous system), respiratory (lung), hepatic (liver) or metabolic disease
* history of mental instability or drug/alcohol abuse within the past 5 years
* Pregnant or nursing; human immunodeficiency virus (HIV) positive; history of cancer within the past 5 years or participation in an investigational trial within the last 30 days
Psychological Aspects in OSA

The research project consists of an observational study. Obstructive Sleep Apnea (OSA) is a condition characterized by recurrent episodes of upper airway collapse during sleep, leading to decreased blood oxygen levels and disruptions of normal sleep patterns. Estimates of its prevalence vary, but its impact on patients' quality of life is evident.

Through a qualitative analysis (semi-structured interviews for both patients and bed partners) and a quantitative analysis (APIM Model), this research aims to explore the perception and awareness of the disease and its impact on the individual and couple's lives of patients with OSA and their bed partners, to assess patients' perceptions of the disease, illness management (CPAP experience) and symptoms, as well as their bed partners' perceptions. Moreover, psychological aspects of living with OSA, such as perceived stress, depression, anxiety, sleep quality, daily sleepiness will be studied to observe the association with Continuous Positive Airway Pressure (CPAP) adherence.

Firstly, a series of semi-structured interviews will be conducted with patients with OSA, at different levels of CPAP adaptation as well as with bed partners of patients who are experiencieng CPAP treatment with OSA.

After that, a quantitative analysis will be conducted to explore dyadic dynamics between patients with OSA and their bed partners.

Eligibility Criteria:
Inclusion Criteria:

* Adult outpatient patients
* over 18 years of age
* Diagnosis of Obstructive Sleep Apnea Syndrome
* Absence of cognitive impairments
* Having a bedpartner

Exclusion Criteria:

* Oncological comorbidities
* Dementia, as reported in the medical record
* Ongoing treatment with phosphodiesterase-5 inhibitors, hypogonadism, or severe lung diseases
* Exacerbations requiring hospitalization or the use of corticosteroids and antibiotics in the last two months
* Lack of consent
* Lack of a bedpartner
Evaluation of Knowledge- Attitude- Practice (KAP) of Intern Dentists in Emergency Management of Traumatic Dental Injuries in Permanent Anterior Teeth

This study aims to evaluate knowledge, Attitude and Practice of intern dentists in emergency management of traumatic dental injuries in permanent anterior teeth in children aged from 6 to 12 years old. A questionnaire survey will be designed to evaluate Knowledge - Attitude - and practice (KAP) of intern dentists who met the eligibility criteria.


Eligibility Criteria:
Inclusion Criteria:

* Intern dentists attending their internship in Faculty of Dentistry- Cairo University, other private university (Modern Science and Arts University- MSA).
* The intern dentists who agree to participate.
* Intern dentists who did not attend Pediatric Dentistry round, Endodontic round, Emergency round and Surgery round at Cairo University.
* Intern dentists irrespective of age and sex.